ReviewACS chemical neuroscience2025
Targeting the Dectin-1 Receptor in Neuroinflammation: Therapeutic Implications for Neuropsychiatric Disorders.
Review in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Fungal β-1,3-glucans: Cell Wall Constituents That Promote Gut Health Through Innate Immune Modulation.Nutrients · 2026Review
- Profiling of 5-hydroxymethylcytosine in blood reveals preferential enrichment at exon-intron junctions and predictive value for Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Intranasal Human NSC-Derived EVs Therapy Can Restrain Inflammatory Microglial Transcriptome, and NLRP3 and cGAS-STING Signalling, in Aged Hippocampus.Journal of extracellular vesicles · 2026Article
- Galectin-3 shapes microglial phenotype through endogenous and exogenous mechanisms.Frontiers in cellular neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exploring the role of the pattern recognition receptor Dectin-1 in neurological diseases emerges as an important target for understanding the biochemical and physiological dynamics of neuropathologies. From this perspective, Dectin-1, protein encoded by the CLEC7A gene, stands out for its important role in antifungal immunity; however, the receptor also proves crucial in enabling the immune response of the central nervous system (CNS). This review highlights how Dectin-1 interacts with microglial cells, as well as the implications of these interactions in inflammatory, neurodegenerative, and psychiatric processes. In this regard, the narrative also revisits relevant discussions on the signaling pathways associated with Dectin-1, including the activation of tyrosine-protein kinase (Syk) and the production of inflammatory cytokines. It is noteworthy that altered expression of Dectin-1 has been observed in various conditions such as Alzheimer's and Parkinson's disease, thereby contributing to neuroinflammatory processes. However, in contrast to this, in depressive disorders, the receptor has shown the ability to modulate the inflammatory response, triggering antidepressant effects. Therefore, understanding the pluralistic role of Dectin-1 in the CNS may offer new scientific perspectives that will enable the development of more targeted therapies for neuroinflammatory and neurodegenerative diseases in different pathological contexts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.